Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.